Bioscience Co. Allegedly Hid Volatility Risks From Investors

By Emilie Ruscoe · April 27, 2026, 4:27 PM EDT

A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re Regencell Bioscience Holdings Limited Securities Litigation

Case Number

1:26-cv-01602

Court

Maryland

Nature of Suit

Securities/Commodities

Date Filed

April 24, 2026